# AtezoTRIBE (NCT03721653)

> FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03721653
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Gruppo Oncologico del Nord-Ovest
- Conditions: Metastatic Colorectal Cancer
- Interventions: Bevacizumab; Irinotecan; Oxaliplatin; L-Leucovorin; 5-fluorouracil; Atezolizumab
- Enrollment: 218
- Primary outcome: Progression Free Survival (PFS)

## Commentary we found

- X threads: 23
- YouTube: 3
- Podcasts: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=atezotribe-nct03721653

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03721653", "email": "<work email>"}; the inbox owner confirms by the emailed link.